Gilead Sciences, Inc. · NASDAQ:GILD
Gilead Sciences — J.P. Morgan Healthcare Conference 2023
22 slides from Gilead Sciences's conference presentation, Jan 9, 2023
Slide 1: Gilead in 2023 and Beyond
Gilead in 2023 and Beyond J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e 9 January 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and un
Slide 3: Gilead in 2023
Gilead in 2023 HIV Portfolio Transformation Fast-Growing Positioned for Impact is Tangible Oncology Business Continued Growth Portfolio with quality, Leading HIV portfolio and Strong commercial depth and breadth, strong poised to shape long-acting performance and clinical financial performance, mark
Slide 4: Strong Progress in First Years of Transformation
Strong Progress in First Years of Transformation Pipeline Bolstered with 81% Increase in 6 New Products with 9 M&A and Partnerships1 Pipeline Portfolio Approved Indications, including 6 in Oncology2 Oncology Virology 58 Inflammation 36 32 12 12 17 8 5 Q119 Q422 Illustration does not include opt-in a
Slide 5: Accelerating Progress with Strategic Priorities
Accelerating Progress with Strategic Priorities Corporate Ambitions Bring 10+ Transformative Be the Biotech employer Deliver Shareholder Value in a Therapies to Patients by 2030 and partner of choice Sustainable, Responsible Manner Key Strategic Priorities for 2023+ Maximize Near- Maximize Impact of
Slide 6: Maintaining HIV Leadership as Growth Continues
Maximize Near-Term Revenue Growth Maintaining HIV Leadership as Growth Continues • $7.5B Biktarvy Q322 YTD sales; +23% from Q321 YTD $12.4B • ~45% U.S. share3 for Biktarvy in Q322; up 4% YoY from Q321 Q322 YTD HIV Revenue • Biktarvy extends lead as #1 in new starts & switch in U.S.4 2033 • Biktarvy
Slide 7: Accelerating Oncology Business with >$2B Annual Run-Rate
Maximize Near-Term Revenue Growth Accelerating Oncology Business with >$2B Annual Run-Rate • ~65% YoY1 growth ~ 85% YoY1 growth $1,040M $485M • • 96% manufacturing • Now reimbursed in reliability Q322 YTD SALES2 16 countries Q322 YTD SALES2 Highlights & Anticipated Milestones Highlights & Anticipate
Slide 8: Reinvesting to Maximize Impact of COVID-19 Therapies
Maximize Near-Term Revenue Growth Reinvesting to Maximize Impact of COVID-19 Therapies Today: Coming: Initiating 2 Pivotal Trials of Oral GS-5245 170+ Countries with remdesivir access1 Standard-Risk High-Risk ~55% COVID patients seeking care are standard-risk 2 ~45% COVID patients seeking care are h
Slide 9: Lenacapavir: Foundation of HIV Long-Acting Portfolio
Maximize Impact of Long-Acting HIV Therapies Lenacapavir: Foundation of HIV Long-Acting Portfolio 2022 Approved for Heavily Prevention Pivotal Trials: Multiple Studies Ongoing Treatment-Experienced PURPOSE-1 and PURPOSE-2 for Treatment ~1-2% of People Living with HIV • Lenacapavir under • 10 potenti
Slide 10: Diverse Pipeline of HIV Long-Acting Treatment Options
Maximize Impact of Long-Acting HIV Therapies Diverse Pipeline of HIV Long-Acting Treatment Options Modality Frequency Backbone Partner Modality Mix Expected to be Once-Daily Lenacapavir Bictegravir Driven by Gilead Innovation Phase 2/3 Combo MTRs 100% Oral Lenacapavir INSTI Oral LA Injectables MTRs
Slide 11: Oncology Portfolio Now Addresses Most Tumor Types
Expand and Deliver on Oncology Programs Oncology Portfolio Now Addresses Most Tumor Types Solid Tumors1 Hematological Cancers2 Triple- HR+ / HER2- Non-Small Acute Negative Bladder Gastric and Large B-cell Follicular Breast Cell Lung Gastroesophageal Lymphocytic Breast Cancer Junction Cancer Lymphoma
Slide 12: Trodelvy is a Cornerstone of our Oncology Program
Expand and Deliver on Oncology Programs Trodelvy is a Cornerstone of our Oncology Program Solid Tumors1 Triple- Negative Breast Bladder Cancer HR+ / HER2- Breast Cancer Non-Small Cell Lung Cancer Gastric and Gastroesophageal Junction Cancer 10 Total ongoing trials 2 Cancer Head and Prostate Small Ce
Slide 13: Comprehensive Trodelvy Breast Cancer Program
Expand and Deliver on Oncology Programs Comprehensive Trodelvy Breast Cancer Program Addressable Addressable TNBC Population1 HR+/HER2- Population1 Neo- NeoSTAR (DCFI Collab) Neo- ~11K NeoSTAR (DCFI Collab) ~44K adjuvant Ph3 Low Risk (WSG Collab) adjuvant ASCENT-05 Adjuvant2 ~40K Adjuvant SASCIA (GB
Slide 14: Trodelvy Could Address Significant Unmet Need
Expand and Deliver on Oncology Programs Trodelvy Could Address Significant Unmet Need When Approved1 Future First and only TROP2 ADC to demonstrate Potential to displace chemotherapy OS benefit in endocrine resistant, chemo in earlier treatment lines2 treated patients with HR+/HER2- mBC HR+/HER2- mB
Slide 15: Comprehensive Lung Clinical Program Underway
Expand and Deliver on Oncology Programs Comprehensive Lung Clinical Program Underway Addressable Gilead Asset External Asset Studies Population1 8 Ongoing NSCLC trials 2 Stage III Domvanalimab Durvalumab PACIFIC-8 ~28K unresectable 6 Ongoing combination trials 2 Domvanalimab Trodelvy Chemotherapy AR
Slide 16: ARC-7: Dom Shows Potential to be Best-in-Class TIGIT
Expand and Deliver on Oncology Programs ARC-7: Dom Shows Potential to be Best-in-Class TIGIT Doublet and triplet showed clinically meaningful efficacy Potentially differentiated safety profile Potential for novel and differentiated IO combinations ARC-7 Interim Analysis 4 1L mNSCLC Stage III NSCLC G
Slide 17: Exploring Full Potential of Magrolimab
Expand and Deliver on Oncology Programs Exploring Full Potential of Magrolimab Solid Tumors Hematological Cancers Triple- Non-Small Gastric and Acute Negative Bladder HR+ / HER2- Large B-cell Follicular Cell Lung Gastroesophageal Lymphocytic Breast Cancer Breast Cancer Junction Cancer Lymphoma Lymph
Slide 18: Advancing and Investing in Magrolimab Programs
Expand and Deliver on Oncology Programs Advancing and Investing in Magrolimab Programs Broad program across hematological cancers and solid tumors Pivotal Trials Phase 2 • No new safety signals identified 1L HR MDS 1L TP53m AML 1L Unfit AML Trial ENHANCE ENHANCE-2 ENHANCE-3 • Gilead remains blinded
Slide 19: Cell Therapy Portfolio Continues to Expand
Expand and Deliver on Oncology Programs Cell Therapy Portfolio Continues to Expand Solid Tumors Hematological Cancers Triple- Non-Small Gastric and Acute Negative Bladder HR+ / HER2- Large B-cell Follicular Cell Lung Gastroesophageal Lymphocytic Breast Cancer Breast Cancer Junction Cancer Lymphoma L
Slide 20: Capital Priorities Unchanged: Returned $5B+ in 2022
Capital Priorities Unchanged: Returned $5B+ in 2022 $3.7B Continue to invest in our business and R&D pipeline Dividends Paid in FY22 while managing expenses Continue ordinary course partnerships and business $1.5B development transactions Debt Repaid in FY22 Grow our dividend $1.4B Repurchase shares
Slide 21: Gilead in 2023
Gilead in 2023 Transformation HIV Positioned for Fast-Growing Impact is Tangible Continued Growth Oncology Business Portfolio with quality, Leading HIV portfolio and Strong commercial depth and breadth, strong poised to shape long-acting performance and clinical financial performance, market followi
Slide 22: Gilead in 2023 and Beyond: Q&A
Gilead in 2023 and Beyond: Q&A J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e 9 January 2023
Gilead Sciences — J.P. Morgan Healthcare Conference 2023 on 6ix